RBM42 is an RNA-binding protein that functions as a critical regulator of both mRNA splicing and translation, with particular importance in oncogenic gene expression and developmental processes. Structurally, RBM42 contains an RNA recognition motif (RRM) domain that enables binding to the 3'-UTR and 5'-UTR regions of target mRNAs 1. Mechanistically, RBM42 operates through dual functions: it facilitates alternative splicing of target genes, particularly by counteracting splicing inhibitory effects of RBM4 1, and it remodels mRNA secondary structures to facilitate translation pre-initiation complex formation 2. As a ribosome-associated protein, RBM42 selectively regulates translation of specific pro-oncogenic transcripts including MYC, JUN, and EGFR in pancreatic ductal adenocarcinoma (PDAC) 3. Clinically, RBM42 expression predicts poor survival in PDAC patients and is necessary for tumorigenesis in vivo 3. Conversely, biallelic loss-of-function variants in RBM42 cause a multisystem neurodevelopmental disorder featuring CNS abnormalities, hearing loss, cardiac defects, and dysmorphic features, with evidence of impaired alternative splicing in neurological and cardiac tissues 4. RBM42 also participates in DNA damage response by regulating p21/CDKN1A expression 1. These findings establish RBM42 as both an oncogenic driver and developmental necessity, representing a potential therapeutic target.